Tradestie Institutional Equity Comparison Engine

IBO vs CLYM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBO Overall Edge

IBO Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, IBO trades at N/M Forward P/E with -12621.0% operating margin (+16.7% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner IBO
IBO N/M vs CLYM N/M Fwd P/E
Growth & Margin Winner IBO
Op Margin -12621.0% vs 0.0% ยท YoY +16.7% vs +0.0%
Momentum & Technical Winner IBO
1Y +862.8% vs +431.6% ยท 52W Pos 67% vs 50%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
1M Return +83.21%
1Y Return +862.75%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-4.05% 1D
Market Cap $608.5M
1M Return +1.22%
1Y Return +431.55%
Forward P/E N/M
Unified AI Score
41.9 / 100 SELL
Tech 38.0 Fund 42.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IBO +862.75% CLYM +431.55% Spread: +431.2 pp (IBO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IBO TTM Op. Margin: -12621.0% CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBO vs CLYM. Trailing 12-month operating profitability (IBO -12621.0% vs CLYM 0.0%) and valuation multiples (IBO N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IBO (5) vs CLYM (4)
Institutional Metric IBO CLYM Criterion Row Winner
Market Capitalization Scale $44.4M $608.5M Larger Scale CLYM
Trailing P/E Ratio Valuation 0.4x N/M Lower Multiple IBO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +16.7% +0.0% Higher Growth IBO
Operating Margin (TTM) Profitability -12621.0% 0.0% Higher Margin CLYM
Net Profit Margin Profitability 4247.4% 0.0% Higher Margin IBO
Return on Equity (ROE) Capital Efficiency 71.2% -29.3% Higher ROE IBO
52-Week Range Position Momentum 67% ($0โ€“$7) 50% ($2โ€“$18) Stronger Trend IBO
Beta / 30D Volatility Risk Regime -6.72ฮฒ ยท 120% Vol 1.50ฮฒ ยท 114% Vol Lower Realized Risk CLYM
Unified Institutional Score Composite Signal 36.8 / 100 (SELL) 41.9 / 100 (SELL) Higher Composite CLYM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IBO vs CLYM Buy Guide
IBO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IBO nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.